DPHA: Update to cover AKITA results, RMC-035 plans and new peptide-platform findings
The Jan 30 R&D update will review Phase 2 AKITA results, FDA feedback and RMC-035's development plan. The Phase 2b POINTER study is planned for Q3 2024 to identify an optimal dose…
DO
By Daniel Okafor · Regulatory Correspondent
Nov 6 15:04 ETSource: TradingView
From the source
Read at tradingview.comDPHA: Update to cover AKITA results, RMC-035 plans and new peptide-platform findings
The Jan 30 R&D update will review Phase 2 AKITA results, FDA feedback and RMC-035's development plan. The Phase 2b POINTER study is planned for Q3 2024 to identify an optimal dose ahead of a pivotal study.
